- Duración
- 01/05/2022 - 30/04/2025
- Coordinador
- Ibrahim Abubakhar (University College of London - UCL)
- Financiadores
- European Commission, Horizon 2021-2024
The END-VOC consortium will support the European and global response to the COVID-19 pandemic and Variants of Concern (VOC) through well-characterised cohorts and linked with existing European and international initiatives.
END-VOC consists of 19 partners in Europe (UK, Spain, Italy, Germany, Netherlands, Norway, Italy), South America (Brazil and Peru), Africa (Mozambique, South Africa, Nigeria and 13 ANTICOV African countries), Middle East (Palestine) and Asia (India, Pakistan, Philippines) with a focus on countries affected by VOCs and VOIs.
Objective
The project aims to elucidate the global circulation of the current and emerging SARS-CoV-2 VOCs and their characteristics, including transmissibility, pathogenicity and propensity to cause reinfection, to support best control strategies and the development of diagnostics; evaluate the impact of VOCs on the effectiveness of different vaccines and vaccination strategies, and assess the implications of VOCs on the choice of optimal treatment options.
END-VOC will also investigate how VOCs alter long-term post-infection sequelae and where new VOCs emerge within hosts using our clinical cohorts.
The project will inform future preparedness and response by working closely with international and national public health organisations and existing cohort consortia. Specific beyond state-of-the-art components of END-VOC include the use of novel phylogenetic prediction tools and mathematical modelling; generation of powerful cohorts through sentinel surveillance in low and middle-income settings and cohorts of travellers to increase our global reach; use of novel predictive modelling of clinical outcomes by VOC and comorbidity/treatment and evaluation of differences in natural and vaccine immunity by VOC; antiviral screening models within cohorts and artificial intelligence-driven tool for the prediction of long COVID.
Total Funding
9,997,114 €
Nuestro equipo
Coordinator (ISGlobal)
-
Elisabeth Cardis Jefa del Programa de Radiación
ISGlobal Team
-
Quique Bassat ICREA Research Professor, Director del Programa de Malaria
-
Gemma Castaño Project Manager
-
Patricia de Llobet Técnica de investigación
-
Elizabet Diago Investigadora Asociada
-
Carlota Dobaño Research Professor
-
Gonzalo Fanjul Director de Análisis
Otros proyectos
Ver proyectos pasadosCOMBACTE
Combatiendo la Resistencia Bacteriana en Europa
Evaluación de estrategias para la erradicación de la enfermedad del Pian
Erradicación del Pian
Novel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
COMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Prioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
HU-MEN (High frequency Ultrasound-based MENingitis screening)
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Xpatial-TB
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
WHIP3TB
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
New antibacterial agents against 'Acinetobacter baumannii'
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Desarrollo de nuevos metaloantibióticos frente a patógenos causantes de infecciones crónicas en pacientes con fibrosis quística
VINCI
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
INTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
AVATAR
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
COVID-PREG
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT)
Estudio piloto para evaluar el potencial de la ivermectina para reducir la transmisión de COVID-19
Encuesta serológica Cendea de Cizur
Cendea de Cizur
CoViproteHCt
Projecte de Recerca en Resposta Immunitària i Epidemiologia de Malalties Infeccioses
Conèixer la propagació. Entendre la protecció
AMR DetecTool
A breakthrough device for the rapid detection of antimicrobial resistance
ANTICOV
Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19
HBV-COMSAVA
Hepatitis B Virus COMmunity Screening and Vaccination in Africans
Stool4TB
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV
Hep C Free Baleares
Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.
CAPTB
Close the Gap, Increase Access, Provide Adequate Therapy
SAFE (Superbug Awareness For Education)
Second Edition
STREESCO
Strengthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19
COVAIR-CAT
Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia
TB-RECONNECT
Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status
SToolNIH
Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring